Đang chuẩn bị liên kết để tải về tài liệu:
Báo cáo y học: "Correction: Interleukin-6: a new therapeutic target"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Correction: Interleukin-6: a new therapeutic target. | Available online http arthritis-research.eom content 8 6 407 Correction Correction Interleukin-6 a new therapeutic target Josef S Smolen1 and Ravinder N Maini2 1 Professor of Medicine Chairman Division of Rheumatology Medical University of Vienna Vienna Austria 2Emeritus Professor of Rheumatology The Kennedy Institute of Rheumatology Division Imperial College London UK Published 17 October 2006 Arthritis Research Therapy 2006 8 407 doi 10.1186 ar2065 This article is online at http arthritis-research.com content 8 6 407 2006 BioMed Central Ltd Following the publication of the above article 1 we noticed that due to an administrative oversight the Competing interests section was incomplete and should read as follows JSS has received financial compensation from and served on advisory boards for Roche and is an investigator in clinical trials of tocilizumab. RNM has received consulting fees from Chugai served on an ad hoc advisory board for Roche and was responsible for the planning and preparation for publication of the Phase II European CHARISMA trial of tocilizumab with and without methotrexate. A patent for coadministration of methotrexate and tocilizumab for the treatment of rheumatoid arthritis of which RNM is named as a co-inventor has been applied for and fully assigned to Chugai. Reference 1. Smolen JS Maini RN Interleukin-6 a new therapeutic target. Arthritis Res Ther 2006 8 Suppl 2 S5. Page 1 of 1 page number not for citation purposes